Personalised management of alveolar soft part sarcoma: a promising phase 2 study
Mené sur 33 patients atteints d'un sarcome de stade avancé ou métastatique, dont 12 patients atteints d'un sarcome alvéolaire des parties molles, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression à 3 mois, et la toxicité d'un traitement combinant axitinib et pembrolizumab (durée médiane de suivi : 14,7 mois)
Medical oncologists have identified approximately 100 different histological subtypes of sarcoma, each of which exhibit specific characteristics and outcomes and require a tailored approach. Accordingly, an accurate biopathological diagnosis of sarcoma is a mandatory first step towards personalised treatment. However, approximately a third of sarcomas are misdiagnosed before the solicitation of an expert second opinion. In The Lancet Oncology, Breelyn A Wilky and colleagues report on the remarkable results of a clinical trial assessing the combined activity of axitinib plus pembrolizumab for advanced sarcoma. The study cohort included 12 patients with alveolar soft part sarcoma (ASPS), which is one of the rarest subtypes of sarcoma and accounts for only 48 (0·5%) of 10 262 sarcomas in the French Nationwide NetSarc database as of December 2014.
The Lancet Oncology , commentaire, 2018